Curated News
By: NewsRamp Editorial Staff
June 16, 2025

Lantern Pharma's AI-Driven Drug Shows Promise in Lung Cancer Trial

TLDR

  • Lantern Pharma's LP-300 combined with chemotherapy shows a durable complete response in a 70-year-old never-smoker with advanced NSCLC, offering a competitive edge in oncology treatments.
  • Lantern Pharma's Phase 2 HARMONIC trial demonstrates LP-300's efficacy in achieving a 57% tumor reduction and full resolution in a patient with advanced NSCLC, utilizing the RADR AI platform for development.
  • LP-300's success in treating a never-smoker with advanced NSCLC represents a significant step forward in addressing unmet needs for patients with limited treatment options, improving quality of life.
  • A 70-year-old never-smoker with advanced NSCLC achieved a durable complete response with Lantern Pharma's LP-300, showcasing the potential of AI in revolutionizing cancer treatment.

Impact - Why it Matters

This news is significant because it showcases the potential of AI in revolutionizing cancer treatment, offering hope to patients with limited options. Lantern Pharma's success with LP-300 could lead to more effective and personalized treatments for never-smoker NSCLC patients, a group that has been historically underserved. The use of AI in drug development not only accelerates the process but also reduces costs, making innovative therapies more accessible. This breakthrough could pave the way for future advancements in oncology, demonstrating the transformative power of technology in healthcare.

Summary

Lantern Pharma (NASDAQ: LTRN) has reported a significant breakthrough in its Phase 2 HARMONIC(TM) trial, where a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieved a durable complete response after being treated with LP-300 in combination with standard chemotherapy. This patient, who had previously undergone three unsuccessful lines of therapy, including Keytruda(R), radiation, and Tagrisso(R), saw a 57% reduction in tumor size initially and later achieved full resolution of lung and adrenal lesions. Remarkably, nearly two years post-treatment, the patient remains progression-free with no significant adverse effects after 21 cycles. This outcome highlights the potential of LP-300, developed using Lantern's RADR(R) AI platform, to meet the urgent needs of never-smoker NSCLC patients who have limited treatment options.

Lantern Pharma is at the forefront of transforming oncology drug discovery and development through its AI and machine learning platform, RADR(R), which utilizes over 200 billion oncology-focused data points. The company's innovative approach has enabled the rapid advancement of its drug pipeline, with programs moving from AI insights to clinical trials in just 2-3 years at a fraction of the traditional cost. For more details on this groundbreaking development, visit the full press release at https://ibn.fm/R0c2m.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma's AI-Driven Drug Shows Promise in Lung Cancer Trial

blockchain registration record for this content.